Figure 3
From: Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer
Performance of the four anti-TAA autoantibodies in the validation cohort. (a, c, e, g) Scatter plots and (b, d, f, h) receiver operating characteristic curve (ROC) for four anti-TAA autoantibodies in the validation cohort. The longest line means median, and the 25th and 75th percentiles are represented by shorter lines.
